Paxista – Nirmatrelvir and Ritonavir are two antiviral medications that are used in combination as a treatment for COVID-19. Here’s a brief description of each medication:
Nirmatrelvir, also known as PF-07321332, is an oral antiviral medication that works by inhibiting the SARS-CoV-2 3CL protease, an enzyme that is necessary for the virus to replicate in human cells. By inhibiting this enzyme, nirmatrelvir helps to stop the virus from multiplying and spreading throughout the body. It is currently used in combination with Ritonavir as part of a treatment regimen for COVID-19.
Ritonavir is an antiviral medication that was originally developed to treat HIV. It works by inhibiting an enzyme called protease, which is needed for the replication of the virus. When used in combination with nirmatrelvir, ritonavir helps to increase the levels of nirmatrelvir in the blood, which may enhance its antiviral effects.
Together, nirmatrelvir and ritonavir have been authorized for emergency use by the U.S. Food and Drug Administration (FDA) to treat COVID-19 in patients who are at high risk of severe illness or hospitalization. These medications are typically used early in the course of the disease, within the first few days of symptom onset. It is important to note that the safety and effectiveness of these medications for treating COVID-19 are still being studied, and they should only be used under the guidance of a healthcare provider.